Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders Equity (Deficit)

v3.22.2
Condensed Consolidated Statements of Changes in Stockholders Equity (Deficit) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2020 $ 1 $ 19,207 $ (32,675) $ (13,467)
Balance (in shares) at Dec. 31, 2020 10,882,495      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Reclassification of Series A warrant from liability to equity $ 0 61,793 0 61,793
Stock-based compensation $ 0 494 0 494
Stock-based compensation (in shares) 40,000      
Exercise of stock options $ 0 10 0 10
Exercise of stock options (in shares) 7,386      
Net and comprehensive loss $ 0 0 (39,014) (39,014)
Balance at Mar. 31, 2021 $ 1 81,504 (71,689) 9,816
Balance (in shares) at Mar. 31, 2021 10,929,881      
Balance at Dec. 31, 2020 $ 1 19,207 (32,675) (13,467)
Balance (in shares) at Dec. 31, 2020 10,882,495      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net and comprehensive loss       (46,150)
Balance at Jun. 30, 2021 $ 2 101,376 (78,825) 22,553
Balance (in shares) at Jun. 30, 2021 16,891,855      
Balance at Mar. 31, 2021 $ 1 81,504 (71,689) 9,816
Balance (in shares) at Mar. 31, 2021 10,929,881      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock and warrants in connection with registered direct offering $ 1 14,999 0 15,000
Issuance of common stock and warrants in connection with registered direct offering (in shares) 3,076,923      
Issuance of common stock in connection with the at-the-market program $ 0 4,067 0 4,067
Issuance of common stock in connection with the at-the-market program (in shares) 900,943      
Issuance of common stock in connection with settlement with investors $ 0 1,614 0 1,614
Issuance of common stock in connection with settlement with investors (in shares) 350,000      
Issuance costs $ 0 0 (1,271) (1,271)
Exercise of Series B warrants $ 0 0 0 0
Exercise of Series B warrants (in shares) 1,629,634      
Stock-based compensation $ 0 463 0 463
Stock-based compensation (in shares) 4,474      
Net and comprehensive loss $ 0 0 (7,136) (7,136)
Balance at Jun. 30, 2021 $ 2 101,376 (78,825) 22,553
Balance (in shares) at Jun. 30, 2021 16,891,855      
Balance at Dec. 31, 2021 $ 2 111,588 (89,368) 22,222
Balance (in shares) at Dec. 31, 2021 18,845,828      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock in connection with the at-the-market program $ 0 1,208 0 1,208
Issuance of common stock in connection with the at-the-market program (in shares) 336,544      
Issuance costs $ 0 (35) 0 (35)
Stock-based compensation $ 0 445 0 445
Stock-based compensation (in shares) 6,970      
Exercise of stock options $ 0 27 0 27
Exercise of stock options (in shares) 24,309      
Net and comprehensive loss $ 0 0 (6,595) (6,595)
Balance at Mar. 31, 2022 $ 2 113,233 (95,963) 17,272
Balance (in shares) at Mar. 31, 2022 19,213,651      
Balance at Dec. 31, 2021 $ 2 111,588 (89,368) 22,222
Balance (in shares) at Dec. 31, 2021 18,845,828      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net and comprehensive loss       (11,522)
Balance at Jun. 30, 2022 $ 2 115,483 (100,890) 14,595
Balance (in shares) at Jun. 30, 2022 20,099,602      
Balance at Mar. 31, 2022 $ 2 113,233 (95,963) 17,272
Balance (in shares) at Mar. 31, 2022 19,213,651      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock in connection with the at-the-market program $ 0 1,858 0 1,858
Issuance of common stock in connection with the at-the-market program (in shares) 877,927      
Issuance costs $ 0 (53)   (53)
Stock-based compensation $ 0 445 0 445
Stock-based compensation (in shares) 8,024      
Net and comprehensive loss $ 0 0 (4,927) (4,927)
Balance at Jun. 30, 2022 $ 2 $ 115,483 $ (100,890) $ 14,595
Balance (in shares) at Jun. 30, 2022 20,099,602